Connect medication expertise, chronic disease management, behavioral support, and social-needs coordination to help patients stay safely engaged in obesity care.
Obesity is a complex chronic disease associated with increased risk of type 2 diabetes, cardiovascular disease, sleep apnea, joint disease, and other serious conditions. Newer anti-obesity medications have expanded treatment options, but medication alone does not address every factor influencing long-term success.
Patients may struggle with side effects, medication cost, coverage restrictions, nutrition access, unrealistic expectations, treatment burden, or loss of support between appointments. Comorbid conditions and other medications must also be considered as weight and clinical status change.
PharmD Live’s Weight Management and Obesity Care Program supports the patient’s existing prescriber through a multidisciplinary model that integrates disease management, clinical pharmacist-led medication review, behavioral support, and attention to social barriers.
The team reinforces the prescriber’s treatment plan and supports realistic, clinically appropriate goals. Patients receive structured education and motivational support related to nutrition, physical activity, sleep, stress, monitoring, and long-term engagement.
The program also coordinates care related to diabetes, hypertension, cardiovascular risk, sleep apnea, kidney disease, and other relevant conditions.
Clinical pharmacists review anti-obesity medications and the complete medication regimen for appropriateness, interactions, tolerability, adherence, contraindication-related concerns, and access barriers. They educate patients on proper use, reinforce safety information, and identify concerns requiring prescriber review.
Sustainable weight management may be affected by food access, medication affordability, insurance coverage, safe opportunities for physical activity, work schedules, transportation, caregiving responsibilities, housing, cultural preferences, and health literacy. The team identifies relevant barriers and helps coordinate appropriate resources.
No. Clinical pharmacists review therapy, educate the patient, identify safety, access, adherence, or tolerability concerns, and send recommendations to the prescriber. The prescriber makes all prescribing and adjustment decisions.
The program can support patients using FDA-approved medications for chronic weight management, subject to the prescriber’s treatment plan, product labeling, patient eligibility, coverage, and program scope. The team reviews the complete regimen rather than focusing on one medication class alone.
The team gathers and documents patient-reported concerns, provides appropriate education within protocol, reinforces prescriber instructions, and communicates clinically significant issues to the authorized prescriber for evaluation.
The team continues to reinforce the prescriber’s maintenance plan, behavioral strategies, monitoring, and follow-up. Medication continuation or adjustment is determined by the prescriber.
Support patients with coordinated medication review, chronic disease management, behavioral engagement, and practical help overcoming barriers.
